EUIPO deputy chief announces bid for top job
EUIPO second-in-command Andrea Di Carlo will run to succeed Christian Archambeau as executive director later this year, he confirmed on Saturday, January 21.
Di Carlo, who has served as deputy executive director since 2019, said in a LinkedIn post that applying for the job was a natural step.
Click here to read the full article.
Nokia, Samsung agree fresh 5G patent licence
Samsung has agreed to pay Nokia for access to 5G patents as part of a cross-licensing deal announced on January 23.
The new agreement covers the period from January 1 and replaces a deal that expired at the end of 2022.
Click here to read the full article.
PTAB reveals reasons for cancelling Novartis patent
The Patent Trial and Appeal Board released its reasoning for cancelling a Novartis patent after a petition from Regeneron on Friday, January 20.
The board made the decision on October 25 2022, but the final written decision was, until Friday, only available to the board and both parties.
Click here to read the full article.
Other articles published by Managing IP this week include:
Five patent trends to watch in Australia in 2023
India bill decriminalising IP offences goes down badly
UKIPO faces copyright owner pushback over AI revolution
Counsel: IP associations must get tough on e-commerce liability
Lenovo infringed InterDigital 4G patent, Court of Appeal rules
Dutch court denies Nokia in latest Oppo twist
Counsel demand bad faith to be used in trademark oppositions
Weekly take: IP juniors’ chance at first-team action long overdue
Elsewhere in IP
UKIPO costs
The UKIPO updated its position on recoverable costs in proceedings on Wednesday, January 25, the first update since 2016. The changes include a £600 ($724) cap on fast-track opposition proceedings. The new scale will apply to proceedings commenced on or after February 1 2023.
BMS lines up AZ
In a lawsuit filed on Monday, January 23, BMS alleged that AstraZeneca’s new CTLA-4 inhibitor Imjudo (rovelizumab), which was approved in the US last year, infringes a pair of patents linked to BMS’s cancer drug Yervoy (ipilimumab). The lawsuit was filed at the District Court for the District of Delaware.
EPO quality meeting
The EPO is to meet with members of the Industry Patent Quality Charter (IPQC) on February 3, the group confirmed on Wednesday, January 25. The IPQC, which has been hankering for a meeting with the EPO, is keen to discuss specific examples of where the quality of granted patents did not meet its expectations. Earlier this month, Managing IP reported that the EPO had agreed to meet the group.
IP5 growth
The world's five largest IP offices granted 1.5 million patents in 2021 (the latest year for which statistics are available), the EPO reported on Tuesday, January 24. The figure is 10% up on the previous year. The report is an annual compilation of patent statistics published by the EPO, the JPO, the KIPO, the CNIPA and the USPTO.
SME help
A call for applications to the EUIPO’s SME Fund 2023 opened on Tuesday, January 23. The SME Fund is a grant scheme designed to help EU SMEs to protect their intellectual property rights.
Rolex rantings
Finally, in yet another David v Goliath trademark battle, Rolex has asked a Devon-based children's clock business to rebrand. According to a BBC report on Thursday, January 19, Rolex wrote to Oyster & Pop and claimed that people may link the educational clocks with its own Oyster Perpetual brand.
